4.8 Article

Stiffening of DU145 prostate cancer cells driven by actin filaments - microtubule crosstalk conferring resistance to microtubule-targeting drugs

期刊

NANOSCALE
卷 13, 期 12, 页码 6212-6226

出版社

ROYAL SOC CHEMISTRY
DOI: 10.1039/d0nr06464e

关键词

-

资金

  1. InterDokMed project [POWR.03.02.00-00-I013/16]
  2. European Union [812772, 801126]
  3. Polish National Science Centre [UMO-2015/19/D/NZ3/00273]

向作者/读者索取更多资源

The study demonstrates that anticancer microtubule targeting drugs can induce cell stiffening by directly perturbing the structural organization of microtubules. While changes in cellular rigidity are typically attributed to remodeling of actin filaments in the cytoskeleton, it is also shown that cell stiffening can be driven by crosstalk between actin filaments and microtubules in MTD-treated cells. These findings improve the interpretation of biomechanical data obtained for living cells in studies of various physiological and pathological processes.
The crucial role of microtubules in the mitotic-related segregation of chromosomes makes them an excellent target for anticancer microtubule targeting drugs (MTDs) such as vinflunine (VFL), colchicine (COL), and docetaxel (DTX). MTDs affect mitosis by directly perturbing the structural organisation of microtubules. By a direct assessment of the biomechanical properties of prostate cancer DU145 cells exposed to different MTDs using atomic force microscopy, we show that cell stiffening is a response to the application of all the studied MTDs (VFL, COL, DTX). Changes in cellular rigidity are typically attributed to remodelling of the actin filaments in the cytoskeleton. Here, we demonstrate that cell stiffening can be driven by crosstalk between actin filaments and microtubules in MTD-treated cells. Our findings improve the interpretation of biomechanical data obtained for living cells in studies of various physiological and pathological processes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据